Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.51 |
| ▸ | RAF1 | P04049 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 15/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197660 | 0.85 | BRAF (0.59) | BRAFRAF1KDR | |
| SCHEMBL461378 | 0.85 | BRAF (0.64) | BRAFRAF1KDR | |
| SCHEMBL345458 | 0.85 | BRAF (0.64) | BRAFRAF1KDR | |
| SCHEMBL346844 | 0.83 | KDR (0.54) | BRAFRAF1KDR | |
| SCHEMBL10197675 | 0.82 | KDR (0.48) | BRAFRAF1KDR | |
| SCHEMBL24932207 | 0.77 | KDR (0.63) | BRAFKDR | |
| SCHEMBL345996 | 0.76 | BRAF (0.63) | BRAFRAF1KDR | |
| SCHEMBL345995 | 0.76 | BRAF (0.63) | BRAFRAF1KDR | |
| SCHEMBL20040800 | 0.75 | KDR (0.66) | BRAFKDR | |
| SCHEMBL15542114 | 0.75 | KDR (0.60) | BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | BRAF 3601/4885RAF1 3360/4885KDR 710/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | BRAF 4293/4885RAF1 4055/4885KDR 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.